DIREKT
Disarming the intravascular innate immune response to improve treatment modalities for chronic kidney disease
| Coordinatore | UPPSALA UNIVERSITET
Organization address
address: SANKT OLOFSGATAN 10 B contact info |
| Nazionalità Coordinatore | Sweden [SE] |
| Totale costo | 8˙502˙311 € |
| EC contributo | 5˙984˙070 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2013-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-12-01 - 2017-11-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UPPSALA UNIVERSITET
Organization address
address: SANKT OLOFSGATAN 10 B contact info |
SE (UPPSALA) | coordinator | 1˙918˙442.00 |
| 2 |
AMYNTAS MONOPROSOPH ANONYMH ETAIRIAEREYNAS TECHNOLOGIAS KAI EMPORIASPHARMAKEYTIKON PROIONTON
Organization address
address: ZEFYROU 25 25 contact info |
EL (VOULIAGMENI) | participant | 1˙012˙326.00 |
| 3 |
UNIVERSITETET I OSLO
Organization address
address: Problemveien 5-7 contact info |
NO (OSLO) | participant | 654˙925.00 |
| 4 |
TECHNISCHE UNIVERSITAET DRESDEN
Organization address
address: HELMHOLTZSTRASSE 10 contact info |
DE (DRESDEN) | participant | 605˙920.00 |
| 5 |
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Organization address
address: Walnut Street, Room P-221 3451 contact info |
US (PHILADELPHIA) | participant | 596˙020.00 |
| 6 |
BACTIGUARD AB
Organization address
address: BIBLIOTEKSGATAN 25 contact info |
SE (STOCKHOLM) | participant | 346˙994.00 |
| 7 |
AARHUS UNIVERSITET
Organization address
address: Nordre Ringgade 1 contact info |
DK (AARHUS C) | participant | 273˙776.00 |
| 8 |
GAMBRO LUNDIA AB
Organization address
address: PO BOX 10101 10101 contact info |
SE (LUND) | participant | 229˙442.00 |
| 9 |
Hycult biotechnology bv
Organization address
address: Frontstraat 2A 2A contact info |
NL (Uden) | participant | 186˙000.00 |
| 10 |
SVERIGES LANTBRUKSUNIVERSITET
Organization address
address: ARRHENIUSPLAN 4 contact info |
SE (UPPSALA) | participant | 126˙225.00 |
| 11 |
AEGEAN CONFERENCES INC. NON PROFITCORPORATION
Organization address
address: PINE STREET 630 630 contact info |
US (PHILADELPHIA) | participant | 34˙000.00 |
| 12 |
UNIVERSITY OF MELBOURNE
Organization address
address: PARKVILLEOFFICE OF THE VICE CHANCELLOR contact info |
AU (MELBOURNE) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Chronic kidney disease is world wide a major cause of end-stage renal disease (ESRD). 800.000 patients in Europe and in the US, respectively, require long-term treatment initially with peritoneal dialysis, followed by hemodialysis and kidney transplantation. Each ESRD patient on hemodialysis costs ≈€40000 to €80000 per year, has extremely poor quality of life and an average life expectancy of only 4 years. Kidney transplantation totally changes life for an ESRD patient who can then return to normal life, but this treatment is hampered by the low number of available kidney grafts. All these treatments are, however, associated with severe adverse reactions that cause damaging thromboinflammation, triggered by the intravascular innate immune system, which lead to poor results and non-function. The overall aim of this project is to clarify the mechanisms and identify nature´s own specific control points of regulation in these adverse reactions in order to be able to significantly improve the quality of hemodialysis devices and kidney grafts by applying these concepts of regulation in hemodialysis and kidney transplantation. We envisage that conveying a novel soluble complement inhibitor to the clinical stage via phase 1/2a clinical studies, creation of nano-profiled surfaces with low activating properties and generation of easy-to-apply one step-coatings for treatment of biomaterials (hemodialysis) and endothelial cell surfaces (kidney grafts) will revolutionize the treatment modalities of ESRD. The feasible hemodialysis treatment periods are anticipated to be extended, combined with an improved quality of life and in kidney transplantation attenuation of innate immune reactions will prolong the life expectancy of the graft and make kidneys more accessible for transplantation. All the novel techniques can be applied to other types of implantations, extracorporeal treatments and transplantation and in the future be used in xenotransplantation and stem cell therapies.'
Altri progetti dello stesso programma (FP7-HEALTH)
NANOGNOSTICS (2009)
Quantum Dot-Based Highly Sensitive Immunoassays for Multiplexed Diagnostics of Alzheimer's Disease
Read MoreAAA-PREVENT (2010)
Effective Environmental Strategies for the Prevention of Alcohol Abuse among Adolescents in Europe
Read MoreFRAILOMIC (2013)
"Utility of omic-based biomarkers in characterizing older individuals at risk for frailty, its progression to disability and general consequences to health and well-being - The FRAILOMIC Initiative"
Read More